



A decorative geometric pattern consisting of overlapping light green and white shapes on the left side of the slide.

Welcome


A headshot of Terry Richardson, a woman with long blonde hair, smiling.

Terry Richardson
Director, Product Development
Academy of Managed Care Pharmacy

Disclaimer

Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.

How to Ask Questions



	AMCP Partnership Forums
	Why Value and Outcomes in Oncology Forum?
	Forum Findings and Recommendations
	2018 AMCP Forum Topics
	Q&A

© 2018 Partnership Forums 4



LEADING CHANGE

On health care issues that are important to you

The live, hands-on AMCP Partnership Forums bring together key decision-makers in managed care, integrated care, the pharmaceutical industry, and others to drive efficiencies and outcomes in integrated care and managed care.



© 2018 Partnership Forums 5 amcp.org

2017 Partnership Forums




- Advancing Value-Based Contracting
- Patient Reported Outcomes – The Missing Link in Defining Value
- Driving Value and Outcomes in Oncology
- Managing Care in the Wave of Precision Medicine




© 2018 Partnership Forums 6

Our Faculty



Marlo Blazer, PharmD, BCOP
Associate Director
Xcenda



Tom Valuck, MD, JD
Partner
Discern Health

Why a Partnership Forum in Oncology?



Oncology is often viewed differently than other disease states by society, and treatments for cancer are often valued differently than treatments for other disease states.

AMCP PARTNERSHIP FORUM

© 2018 Partnership Forums 8

Oncology Forum Goals

1. Define solutions for addressing causes of patients' financial burdens for cancer care
2. Understand which oncology-specific quality measures are important
3. Prioritize the gaps related to the use of pharmaceuticals in measuring oncology outcomes
4. Develop a list of recommendations for how a collaboration of payers, providers, and AMCP may drive improvements in oncology care



© 2018 Partnership Forums

9

Forum Participants

30+ participants from health plans, integrated delivery systems, pharmacy benefit managers, employers, data and analytics experts, biopharmaceutical companies and government agencies, including:


AbbVie	Kaiser Permanente
Aetna	Koontz Oncology Consulting LLC
American Society of Clinical Oncology	Lilly
Amgen	Magellan Rx Management
AstraZeneca	Massachusetts General Hospital Cancer Center
Baylor Scott & White Health	Merck
Biologics - McKesson Specialty Health	Milliman
Diplomat Specialty Pharmacy	National Comprehensive Cancer Network (NCCN)
Discern Health	NEHI-Network for Excellence in Health Innovation
Express Scripts	Patient Advocate Foundation & National Patient Advocate Foundation
Foundation Medicine	Sanofi
Fred Hutchinson Cancer Research Center	Takeda Oncology
Genentech, Inc.	University of Chicago
Gilead Sciences, Inc.	UPMC Health Plan
Hospice & Palliative Care Network of Maryland	Xcenda



© 2018 Partnership Forums

10

Forces Driving Change in Oncology




© 2018 Partnership Forums 11

What is High Value Care?



© 2018 Partnership Forums 12

How Do We KNOW When We Have High Value Care?



© 2018 Partnership Forums 13

The Financial Burden of Cancer Care on the Patient


- 1 Financial burden has the potential to harm patient quality of life, clinical outcomes, and adherence to treatment.
- 2 The burden on patients is increasing.
- 3 In addition to the direct health care cost, patients may have reduced income, may struggle to meet the costs for transportation, housing, food, and childcare, and may put a burden on caregivers who may also experience reduced income.



© 2018 Partnership Forums 14


Addressing the Patient Financial Burden

Patient costs may be negatively affected by:




© 2018 Partnership Forums 15

Strategies to Address Patient Financial Burden



© 2018 Partnership Forums 16

Strategies to Address Patient Financial Burden: Insurance Benefit Designs



© 2018 Partnership Forums 17

The move toward value-based care requires a transparent, agreed-upon set of criteria for evaluating outcomes and defining whether an intervention provides value, partial value, or no value.

Utilization of Quality Measures

Organizations request or require health metrics for many reasons, including:

1	2	3	4	5
Tracking population and individual health	Assessments of health care quality and patient experience	Professional performance requirements	Transparency monitoring	Public reporting and benchmarking

NOTE: Definitions of value for these metrics may mean different things for different stakeholders.



© 2018 Partnership Forums 19

Quality Measures Role in Improving Care

Quality measures should be:

- 1 Used to improve outcomes and the patient experience
- 2 Used to make the healthcare system safer and more efficient
- 3 Meaningful to multiple stakeholders
- 4 Easily measurable and based on outcomes
- 5 Selected based on purposes of measure, such as cost, appropriateness of treatment, or quality of life



© 2018 Partnership Forums 20

Identifying Issues for Refining Quality Measures

There are a number of overarching issues to be addressed to make quality measures effective for driving value:

- 1 Consistent access to data and greater interoperability among data systems
- 2 Robust, up-to-date, and meaningful measures to assess oncology care that matters to patients
- 3 Process for re-evaluating and retiring measures at regular intervals
- 4 Inclusion of PROs as appropriate



© 2018 Partnership Forums 21

Quality and Performance Measurement and Reporting

- 1 Use collaboration to get agreement on what is measured and reported
- 2 Focus on a few (e.g., 5 or fewer) measures/outcomes
- 3 Focus on how changing can benefit physicians/clinics and patients
- 4 Look at the evidence and best practice before developing new measures or reports
- 5 Define the purpose (why) of the measurement (e.g., improve care, reimbursement, value-based contract)



© 2018 Partnership Forums 22

Identified Gaps in Quality Measurement

Measure Type	Gap	AMCP Oncology Partnership Forum	NQF	CMS	CQMC
Process	Appropriate use of chemotherapy	X			X
	Monitoring adherence to therapy	X			
	Entry into clinical trial	X			
	Use of advance directives	X			
Value	Total cost of care	X			X
	Appropriate care (underuse or overuse)	X	X		X
	Cost of care by setting	X			
Clinical Outcome	Overall survival	X	X		X
	Disease-free survival	X	X		X
	Stage-specific survival	X	X		X
	5-year cure rate		X		X
	Medication adherence	X	X		
	Quality of life/functional status	X	X	X	X
	Pain control	X		X	X
	Functional status	X		X	X
	Staging	X			



Identified Gaps in Quality Measurement (cont.)

Measure Type	Gap	AMCP Oncology Partnership Forum	NQF	CMS	CQMC
Patient-Centered/ experience	Personalized medicine		X		
	Patient-reported outcomes	X			
	Shared decisions making	X		X	X
	Symptoms and complications of therapy/adverse events	X	X		
	Total cost to patient	X			
	Return to work (patient/caregiver)	X			
Population-specific	End-of-life and palliative care (e.g. use/referral rate)	X	X	X	
	Managing and treating general cancer pain	X			
	Emergency department visits at end of life	X			
Safety	Appropriate chemotherapy dosing	X			



Recommendations for New Cross-Cutting Measures

Measurement	Quality & Performance Measurement Reporting
Use collaboration to get agreement on what is measured and reported	✓
Focus on a few (e.g., 5 or less) measures/outcomes	✓
Focus on how changing can benefit physicians/clinics and patients	✓
Look at the evidence and best practice before developing new measures or reports	✓
Define the purpose (why) of the measure	✓
Use multiple stakeholders, including patients, to prioritize what is important	✓

*activities of daily living, employment, caregiver stress, functional status



© 2018 Partnership Forums

25

Recommendations for New Cross-Cutting Measures

Measurement	Patient
Impact on Patient*	✓
Adherence (efficacy and adherence with oral oncologics)	✓
Survivorship	✓
24/7 access to clinicians	✓
Pain management/distress	✓
Palliative care discussions	✓
Patient education	✓
Hospital admissions and ER visits toward end of life	✓
Advance care directives	✓
Shared decision making	✓

*activities of daily living, employment, caregiver stress, functional status



© 2018 Partnership Forums

26

Recommendations for New Measure Development and Reporting

Measurement	Financial	Treatment Related
Total Costs	✓	
Impact of treatment setting on costs	✓	
Financial issues for patients	✓	
Hospital readmissions	✓	
Timelines and accuracy of diagnosis		✓
Appropriate use of therapy		✓
Appropriate use of companion diagnostics/ Relationships between tumor markers and treatments/ Targeted drug utilization		✓
Efficacy (outcomes and surrogate measures of outcomes)		✓
Treatment toxicity		✓


*activities of daily living, employment, caregiver stress, functional status



© 2018 Partnership Forums

27

Considerations for Measuring Value of Pharmaceuticals



Measures that are Most Useful in Value Frameworks: Legend










© 2018 Partnership Forums

29

Outcome and Value Measurements for Oncology Pharmaceuticals

Clinical Outcomes	Alignment of Participant Top Prioritization
Overall survival (OS)	
Progression-free survival (PFS)	
Disease-free survival (DFS)	
Patient Reported Outcome (PRO)	
Response rate (RR)	
Partial vs. complete	
Palliation of symptoms	
Hazard ratio (death)	






Outcome and Value Measurements for Oncology Pharmaceuticals

Drug and Healthcare Cost	Alignment of Participant Top Prioritization
Drug acquisition cost per month	
Adjuvant therapy drug acquisition cost per month	
Total treatment cost	
Total drug cost per person	
Total drug cost to payer	
Average sales price/average wholesale price	
Cost to health care system	



© 2018 Partnership Forums 31







Outcome and Value Measurements for Oncology Pharmaceuticals

Safety / Toxicity	Alignment of Participant Top Prioritization
Grade 3/4	
Severe side effects	
Side effect frequency	
Probability of discontinuation	
Effect on daily life	



© 2018 Partnership Forums 32

Outcome and Value Measurements for Oncology Pharmaceuticals

Other Measures	Alignment of Participant Top Prioritization
Treatment-free interval	
Tail of the curve	
Quality of life/palliation	
Disease burden	
Unmet need	
Novelty	

Additional Measures of Pharmaceutical Value

- 1 Expectations of therapy
- 2 Time to treatment switch
- 3 Adherence to pathways
- 4 Treatment duration
- 5 PROs as a function of safety
- 6 Risk of long term side effects
- 7 Society costs

Summary

As value-based care models evolve in oncology, they hold promise to be useful for designing payment models for innovative treatments that emerge for other disease states.

Value and Outcomes in Oncology

- Ongoing multi-stakeholder forums discussing the specific strategies and standards for ushering in the era of precision medicine
- Working collaboratively with key stakeholders to identify a pathway to using PROs in a value-based health care system



Presented: AMCP Annual Conference, April 2018

Published: Journal of Managed Care and Specialty Pharmacy, June 2018

Our Sponsors



© 2018 Partnership Forums 37


2018 FORUM TOPICS

- 1 Designing Benefits and Payment Models for Innovative High-Investment Medications
- 2 Managing Total Cost of Care Through Medical and Pharmacy Data Integration
- 3 Building the Foundation for Patient-Reported Outcomes: Infrastructure and Methodologies
- 4 Integrated Delivery Network's Role in Value-Based Agreements for Pharmacy and Medical Benefits



© 2018 Partnership Forums 38 amcp.org

Reminder: How to Ask Questions



Upcoming Webinars
www.amcp.org/calendar